[CLSTR]
< Back to situations

[ORGANIZATION]

Wegovy

Featured in 74 tracked stories · first seen

Situations

[ACTIVE] [BUSINESS] [GB] [NL]

Heineken response to GLP-1 medication impact

2 clusters · 16 sources · last updated

Latest: Heineken warns of sales risks due to rising weight-loss drug use

Heineken has advised British hospitality venues to prepare for potential revenue declines caused by the rising popularity of GLP-1 weight-loss medications, such as Ozempic and Wegovy. The company identified two primary

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

313 clusters · 1156 sources · last updated

Latest: L’Oreal reports weight loss drugs are impacting beauty sales

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, and neurodegenerative health. Cardiovascular benefits rema

[ACTIVE] [HEALTH] [US] [BR] [DK]

Novo Nordisk pivots strategy to counter patent cliff

112 clusters · 548 sources · last updated

Latest: Novo Nordisk faces intense competition in obesity drug market

Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide in the early 2030s. To diversify its portfolio and counter competition from Eli Lilly,

[ACTIVE] [HEALTH] [US] [GB] [SE]

Expanding therapeutic uses and regulatory approvals for GLP-

33 clusters · 154 sources · last updated

Latest: GLP-1 medications show weight loss challenges regarding muscle mass and maintenance

Medical research continues to expand the therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. While semaglutide is widely used for weight loss and diabetes, new evidence suggests it may slow

[QUIET] [HEALTH] [FR] [PL] [US]

Wegovy semaglutide treatment developments

2 clusters · 4 sources · last updated

Latest: Wegovy oral tablet to launch in France by November 2026

Novo Nordisk is expanding the availability and administration methods of its semaglutide-based obesity medication, Wegovy. In Poland, the company is introducing a higher 7.2 mg weekly injectable dose, which clinical stud

[QUIET] [CRIME] [KR]

South Korean illegal drug and obesity medication surge

2 clusters · 7 sources · last updated

Latest: South Korea blocks 949 illegal online sales of GLP-1 obesity drugs

South Korean authorities have reported a significant rise in the illegal importation of narcotics and counterfeit obesity medications. Drug seizures at airports, particularly Incheon International Airport, have increased

[QUIET] [HEALTH]

Dr. Ian Smith menopause nutrition guidance

2 clusters · 12 sources · last updated

Latest: Dr. Ian Smith discusses menopause nutrition and weight loss

Dr. Ian Smith has released a new book, ‘The New Menopause Kitchen: Targeted Nutrition to Help Fight Symptoms, Lose Weight, and Thrive in Perimenopause, Menopause, and Beyond’. The work was developed in response to reques

[QUIET] [BUSINESS] [DK] [US]

Novo Nordisk Wegovy marketing and ethical scrutiny

2 clusters · 6 sources · last updated

Latest: Novo Nordisk shifts Wegovy marketing following FDA warnings

Novo Nordisk is facing regulatory and ethical scrutiny regarding the marketing and patient support strategies for its weight-loss medication, Wegovy. In Denmark, the Ethical Committee for the Pharmaceutical Industry (En

[QUIET] [BUSINESS] [DK] [IT] [NO]

Novo Nordisk corporate rebranding and health initiatives

3 clusters · 42 sources · last updated

Latest: Novo rebrands to simplify identity and signal future medical innovations

Novo Nordisk has initiated several strategic moves regarding its brand identity and public health engagement. The company entered a partnership with the Norwegian football club Bodø/Glimt to promote physical activity and

Also covered in